Protherics PLC announces Blocklisting Interim Review


Cheshire, UK -- (MARKET WIRE) -- April 10, 2007 --

                                 Protherics PLC



                         6 monthly Block Listing Return

                         Individual Unapproved Options







London, UK; Brentwood, TN, US: 10 April 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that, today, the following 6 monthly block listing
return in respect of the Company's Individual Unapproved Option arrangements has
been lodged with the FSA in accordance with Listing Rule 3.5.6.




Name of applicant:                                        Protherics PLC
Name of scheme:                                           Individual Unapproved Option arrangements
Period of return:                          From:          9 October 2006         To:       8 April 2007
Balance under scheme from previous return:                640,000
The amount by which the block scheme has been increased,  Nil
if the scheme has been increased since the date of the
last return:
Number of securities issued/allotted under scheme during  Nil
period:
Balance under scheme not yet issued/allotted at end of    640,000
period
Number and class of securities originally listed and the  810,000 Ordinary Shares (date of admission: 8 April 2005)
date of admission
Total number of securities in issue at the end of the
period
                                                          339,169,625







                                   |  Ends  |





For further information please contact:


Protherics
Nick Staples, Director of Corporate Affairs                                     +44 (0) 7919  480510
Julie Vickers, Company Secretary                                                +44 (0)1928 518000

Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble                                                 +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt                                         +1 212 850 5600



Or visit  www.protherics.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange